Morepen Laboratories Ltd.

NSE: MOREPENLAB  SECTOR: Pharmaceuticals & Drugs

57.65
-1.65 (-2.78%)

Price Summary

Today's High

₹ 60.35

Today's Low

₹ 56.8

52 Week High

₹ 72.05

52 Week Low

₹ 15.5

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.

Company Essentials

Market Cap

2593.248060295 Cr.

Enterprise Value

2688.298060295 Cr.

No. of Shares

44.9826203 Cr.

P/E

27.52

P/B

5.83

Face Value

₹ 2

Div. Yield

0%

Book Value (TTM)

₹  9.8922

CASH

38.0324 Cr.

DEBT

133.0824 Cr.

Promoter Holding

34.54%

EPS (TTM)

₹  2.0952

Sales Growth

10.4210860783704%

ROE

11.0596567320018 %

ROCE

9.2916821481714 %

Profit Growth

4.08252707050642 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1w1m3m6m1Yr3Yr5Yr

* Prices are based on daily market changes.

Valuation Chart 1w1m3m6m1Yr3Yr5Yr

* The chart is based on the standalone earnings of the company.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

Sales Growth (in Cr.)

1 Year10.42%
3 Year13.09%
5 Year16.42%

Profit Growth (in Cr.)

1 Year13%
3 Year11.75%
5 Year123.31%

ROE%

1 Year11.06%
3 Year10.97%
5 Year10.28%

ROCE %

1 Year9.29%
3 Year8.76%
5 Year8.41%

Debt/Equity

0.4331

Price to Cash Flow

238.78

Interest Cover Ratio

20.0504701397713

CFO/PAT (5 Yr. Avg.)

1.6971319196182

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2021 34.54 0
Dec 2020 34.54 0
Sep 2020 34.54 0
Jun 2020 34.54 0
Mar 2020 34.54 0
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy Interest coverage ratio of 20.0504701397713.
  • The company has an efficient Cash Conversion Cycle of 28.4700306648877 days.

 Limitations

  • The company has shown a poor revenue growth of 13.0946873675172% for the Past 3 years.
  • Tax rate is low at 13.7365334642413.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021
Net Sales 189.15 243.26 314.6 290.46 264.11
Total Expenditure 172.8 217.99 285.27 260.35 236.45
Operating Profit 16.35 25.27 29.33 30.11 27.65
Other Income 1.72 1.33 3.73 2.84 3.87
Interest 0.62 0.29 0.29 1.27 -0.05
Depreciation 7.97 7.47 7.16 7.05 6.43
Exceptional Items 0 0 0 0 0
Profit Before Tax 9.48 18.85 25.62 24.64 25.14
Tax 0 0 0 0 0
Profit After Tax 9.48 18.85 25.62 24.64 25.14
Adjusted EPS (Rs) 0.02 0.04 0.06 0.05 0.06

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Net Sales 452.46 547.51 560.83 717.24 791.99
Total Expenditure 388.26 487.02 500.56 652.22 727.52
Operating Profit 64.2 60.49 60.27 65.02 64.47
Other Income 1.17 3.72 3.54 3.67 9.42
Interest 10.41 7.47 4.29 2.07 1.97
Depreciation 34.92 33.56 33.4 38.01 34.43
Exceptional Items -4.4 0 0 0 0
Profit Before Tax 15.64 23.17 26.12 28.61 37.48
Tax -0.14 0 0 0 5.15
Net Profit 15.78 23.17 26.12 28.61 32.33
Adjusted EPS (Rs.) 0.35 0.52 0.58 0.64 0.72

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity and Liabilities
Share Capital 209.61 89.96 89.96 89.96 89.96
Total Reserves 119.24 134.38 160.6 187.5 217.29
Borrowings 42.74 0.94 2.7 1.79 0.92
Other N/C liabilities 12.47 14.34 15.18 19.32 24.43
Current liabilities 150.79 308.19 322.21 320.82 329.38
Total Liabilities 534.86 547.81 590.65 619.39 661.99
Assets
Net Block 216.36 191.29 182.1 152.59 134.84
Capital WIP 0 0 0 0 0
Investments 117.69 117.69 117.69 117.69 118.78
Loans & Advances 53.92 59.41 63.47 65.49 59.83
Other N/C Assets 0 0.85 0.27 0.28 0.28
Current Assets 146.88 178.56 227.11 283.33 348.26
Total Assets 534.86 547.81 590.65 619.39 661.99
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit Before Tax 20.04 22.55 26.12 28.61 37.48
Adjustment 45.32 40.92 37.86 38.36 34.23
Working Capital Changes -11.09 -14.23 -2.72 -52.4 -55.33
Tax Paid 0.14 0 0 0 -5.52
Operating Cash Flow 50.01 49.24 61.25 14.58 10.86
Investing Cash Flow -27.08 -14.67 -24.28 -10.34 -12.08
Financing Cash Flow -27.89 -31.29 -37.67 -0.35 4.65
Net Cash Flow -4.97 3.29 -0.69 3.89 3.43

Corporate Actions

Ratings & Research Reports

No Credit and Research reports exist for this company.
Report us

Company Presentations

Company News

Morepen Laboratories Stock Price Analysis and Quick Research Report. Is Morepen Laboratories an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Morepen Laboratories and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 10.8605 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Morepen Laboratories has a Debt to Equity ratio of 0.4331 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Morepen Laboratories , the EPS growth was 12.9990633824475 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Morepen Laboratories has OPM of 8.13977596108221 % which is a bad sign for profitability.
     
  • ROE: Morepen Laboratories have a average ROE of 11.0596567320018 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Morepen Laboratories

X